NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Genre Technical Report Remove constraint Genre: Technical Report Recently Added Within 3 Months Remove constraint Recently Added: Within 3 Months Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

1. Advancing primary prevention in human services. Opportunities for people with lived experience

2. Advancing primary prevention in human services. Key considerations for policy designers and funding partners

3. Advancing primary prevention in human services. Key considerations for administrators and practitioners

4. Medicare Part B drugs: trends in spending and utilization, 2008-2021

5. Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act

6. Updated Medicare FFS telehealth trends by beneficiary characteristics, visit specialty, and state, 2019-2021

9. Does schooling improve cognitive abilities at older ages?: causal evidence from nonparametric bounds

13. Medicare payment policy for post-acute care in nursing homes

14. Expiration of the USDA Supplemental Nutrition Assistance Program (SNAP) emergency allotments: increased food insufficiency highlights inadequacy of SNAP benefits after thrifty food plan revisions

15. To protect and serve: clarifying the role of law enforcement in the emergency department

16. Effect of nudges to clinicians, patients, or both to increase statin prescribing: a cluster randomized clinical trial

18. CMS has opportunities to strengthen states’ oversight of Medicaid Managed Care Plans’ reporting of medical loss ratios

21. During the initial COVID-19 response, HHS personnel who interacted with potentially infected passengers had limited protections

26. Inaccuracies in Medicare’s race and ethnicity data hinder the ability to assess health disparities

33. FDA’s approach to overseeing online tobacco retailers needs improvement

40. COVID-19 mortality rates across noncore, micropolitan, and metropolitan counties by community characteristics, December 2020-January 2021

41. State-based recommendations to support rural ambulance agencies

43. The role of telehealth in achieving a high performing rural health system: priorities in a post-pandemic system

52. More than a thousand nursing homes reached infection rates of 75 percent or more in the first year of the COVID-19 pandemic: better protections are needed for future emergencies

54. High rates of prior authorization denials by some plans and limited state oversight raise concerns about access to care in Medicaid managed care

59. Home health agencies failed to report over half of falls with major injury and hospitalization among their Medicare patients

63. In five states, there was no evidence that many children in foster care had a screening for sex trafficking when they returned after going missing

64. Certain Medicare beneficiaries, such as urban and Hispanic beneficiaries, were more likely than others to use telehealth during the first year of the COVID-19 pandemic

66. For Medicaid-enrolled children diagnosed with lead toxicity in five states, documentation reviewed for diagnoses and treatment services raises concerns

67. The ripple effect of firearms: how families, communities, and society in the U.S. are affected by firearms

69. Meeting the behavioral health needs of farm families in times of economic distress

70. Nursing homes in rural America: a chartbook : key facts about nursing home availability in rural America

71. Health insurance marketplaces: issuer participation trends in non-metropolitan places, 2014-22

72. An insurance profile of rural America: chartbook : key facts about insurance coverage and healthcare access in rural America

73. The evolution of hospital designations and payment in the U.S: implications for rural hospitals

81. Institutional review board (IRB) review of individual patient expanded access submissions for investigational drugs and biological products: guidance for IRBs and clinical investigators

82. Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process": guidance for industry and Food and Drug Administration staff

87. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry

88. Wholesale distributor verification requirement for saleable returned drug product and dispenser verification requirements when investigating a suspect or illegitimate product: compliance policies : guidance for industry

90. Voluntary consensus standards recognition program for regenerative medicine therapies: guidance for industry

94. Compliance policy regarding blood and blood component donation suitability, donor eligibility and source plasma quarantine hold requirements: guidance for industry

96. Human prescription drug and biological products: labeling for dosing based on weight or body surface area for ready-to-use containers : “dose banding” : guidance for industry